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Introduction creatinine was 1.1 mg/dl, WBC was 5800/ml, Hgb 10.4 g/dl, MCV 93.1 fl and platelet 176 000/ml. Hepatitis A, B and C virus antibodies were all negative. Parvovirus B19 was first identified serendipitously in Blood and urine cultures were positive for CMV. human sera from blood donors in 1975. Shortly thereCytomegalovirus IgG ( EIA) antibody was 2.1 (negaafter it was found to be responsible for erythema tive <1.1) and IgM (IFA) antibody was 640 units infectiosum in children and transient aplastic anemia (negative <10). Parvovirus B19 IgG and IgM (EIA) in patients with chronic haemolysis. It can also cause antibodies were 2.4 and 6.21 (negative <1.2) respectchronic marrow hypoplasia or aplasia in patients with ively. Liver biopsy showed nonspecific focal hepatic immunosuppression [1] [2] [3] . It has recently been necrosis. The patient was given intravenous ganciclovir. reported to cause anemia following cadaveric renal Transaminase levels returned to normal while the transplant [4] [5] [6] [7] [8] [9] [10] [11] [12] . We describe an unusual case of haemoglobin level decreased gradually. There appears to be a single and stable antigenic type Treatment with intravenous immunoglobulin, presumably due to the neutralizing antibody in the preof B19 virus such that infection is usually followed by life-long immunity. Parvovirus B19 usually occurs paration, has been effective. However, conservative management with blood transfusion may be adequate between the ages of 4 and 11 years. Over 50% of adults are seropositive indicating past infection [13] . as in cases 1 and 3, and the current case.
Recurrence of FSGS after renal transplant has been However, in patients with chronic haemolysis or with an immunosuppressed state, parvovirus B19 infection well documented [17, 18] . However, the question of whether parvovirus or other viral infections may have may become protracted and cause prolonged anemia and even aplastic anaemia [3] .
had any role in inducing FSGS in case 9 and the recurrence of FSGS in our case is intriguing. Wierenga Parvovirus B19 has been reported in different solidorgan transplants such as renal, heart and liver et al. [19] recently reported an association of glomerulonephritis, including FSGS, after parvovirus infec-[14-16 ]. Parvovirus B19 infection is relatively uncommon in bone marrow transplantation presumably tion in sickle cell patients. A large prospective study is needed to confirm this hypothesis. because of the routine use of intravenous immunoglobulin that contains protective parvovirus B19 antibodies Post-transplant CMV infection as a result of severe immunosuppression is well described in the literature.
[16 ]. The case reports of parvovirus B19 infections complicating renal transplants are summarized in A CMV-positive donor, as in our case, is the most significant risk factor [20] . Prophylactic use of acyclo- Table 1 . Most cases involved cadaveric donors except the current case. The age of the recipients ranged from vir, ganciclovir or anti-CMV immunoglobulin has been recommended in transplantation from CMV-positive 7 to 62 years with a median of 45 years and the donors ages ranged from 18 months to 57 years.
donors [20] [21] [22] . Despite receiving prophylactic acyclovir, our patient developed CMV and herpes simplex While the mode of transmission of parvovirus infection in a normal host is mostly through the respiratory (and parvovirus B19) infections.
Mycophenolate mofetil has been shown to reduce tract, it is less defined in the transplant setting. Donor tissues were investigated in cases 2, 4 and 5. Parvovirus acute graft rejection by 50% with principal side-effects being gastrointestinal toxicity and perhaps an increase DNA was detected only in the donor serum of case 5. In case 4, while parvovirus DNA was not detected in in cytomegalovirus infection [23, 24] . Interestingly, a similar case of cytomegalovirus colitis has recently the donor serum, it was present in the patient serum taken just before transplant suggesting that the infec-been reported in a CMV-seropositive renal transplant recipient on immunosuppressive therapy including tion was not donor-related. Similarly in cases 6 and 9, parvovirus infection was documented in the patient mycophenolate mofetil [25] . To date, however, the role of the mycophenolate mofetil in CMV infection is far sera stored prior to renal transplant. It is conceivable that the mode of transmission may or may not be from conclusive. In contrast, Neyts et al. [26 ] recently demonstrated that topical mycophenolate mofetil may donor related. Reactivation of parvovirus infection, as with cytomegalovirus infection, is also possible.
actually potentiate the activities of acyclovir and gan- 
